QC
JAZZ icon

Quadrature Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Quadrature Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
7,796
+2,208
+40% +$386K 0.02% 462
2025
Q4 		$950K Buy
+5,588
New +$857K 0.01% 532
2016
Q3 		– Sell
-25,154
Closed -$3.56M – 644
2016
Q2 		$3.56M Buy
+25,154
New +$3.71M 0.26% 96

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Quadrature Capital's JAZZ Position: Q1 2026 in Review

Quadrature Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 40% in Q1 2026, buying an estimated $386K and bringing the position to 7,796 shares worth $1.47M. The position accounts for 0.02% of the portfolio, ranked #462.

Quadrature Capital first reported a position in JAZZ in Q2 2016 and has held it in 3 quarters since. The position peaked at $3.56M in Q2 2016. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Quadrature Capital held 7,796 shares of Jazz Pharmaceuticals worth $1.47M as of Q1 2026.
  • Quadrature Capital bought 2,208 Jazz Pharmaceuticals shares in Q1 2026, an estimated $386K.
  • Jazz Pharmaceuticals made up 0.02% of Quadrature Capital's portfolio in Q1 2026, its #462 holding.
  • Quadrature Capital first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 3 quarters since.
  • Quadrature Capital's Jazz Pharmaceuticals position peaked at $3.56M in Q2 2016.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.